EP2331574A2 - Antikörper mit mannose-bindender lectineffektorfunktion zur hemmung pathologischer entzündungszustände - Google Patents

Antikörper mit mannose-bindender lectineffektorfunktion zur hemmung pathologischer entzündungszustände

Info

Publication number
EP2331574A2
EP2331574A2 EP09812332A EP09812332A EP2331574A2 EP 2331574 A2 EP2331574 A2 EP 2331574A2 EP 09812332 A EP09812332 A EP 09812332A EP 09812332 A EP09812332 A EP 09812332A EP 2331574 A2 EP2331574 A2 EP 2331574A2
Authority
EP
European Patent Office
Prior art keywords
mbl
composition
antibody
antibodies
constant region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP09812332A
Other languages
English (en)
French (fr)
Inventor
Gregg J. Silverman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of EP2331574A2 publication Critical patent/EP2331574A2/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP09812332A 2008-09-05 2009-09-04 Antikörper mit mannose-bindender lectineffektorfunktion zur hemmung pathologischer entzündungszustände Withdrawn EP2331574A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19106708P 2008-09-05 2008-09-05
PCT/US2009/056125 WO2010028306A2 (en) 2008-09-05 2009-09-04 Antibodies with mannose binding lectin effector function for inhibiting pathologic inflammatory conditions

Publications (1)

Publication Number Publication Date
EP2331574A2 true EP2331574A2 (de) 2011-06-15

Family

ID=41797898

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09812332A Withdrawn EP2331574A2 (de) 2008-09-05 2009-09-04 Antikörper mit mannose-bindender lectineffektorfunktion zur hemmung pathologischer entzündungszustände

Country Status (3)

Country Link
US (1) US20110159000A1 (de)
EP (1) EP2331574A2 (de)
WO (1) WO2010028306A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2526119T3 (en) 2010-01-19 2018-07-30 Harvard College Manipulated opsonin for pathogen detection and treatment
WO2013012924A2 (en) 2011-07-18 2013-01-24 President And Fellows Of Harvard College Engineered microbe-targeting molecules and uses thereof
CN104284984B (zh) 2012-02-29 2017-10-13 哈佛大学校长及研究员协会 抗生素药敏性的快速测试
US10551379B2 (en) 2013-03-15 2020-02-04 President And Fellows Of Harvard College Methods and compositions for improving detection and/or capture of a target entity
AU2014268603B2 (en) 2013-05-21 2018-03-22 President And Fellows Of Harvard College Engineered heme-binding compositions and uses thereof
EP3912986B1 (de) 2013-12-18 2023-12-13 President and Fellows of Harvard College Crp-erfassung/-detektion von bakterien
CN108289928A (zh) 2015-08-06 2018-07-17 哈佛大学校长及研究员协会 改进的微生物-结合分子和其用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ561218A (en) * 2005-02-07 2011-04-29 Univ California Methods for reducing the symptoms of autoimmunity and inflammation using binding proteins against antigens exposed on dead or dying cells

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2010028306A2 *

Also Published As

Publication number Publication date
WO2010028306A3 (en) 2010-07-01
US20110159000A1 (en) 2011-06-30
WO2010028306A2 (en) 2010-03-11

Similar Documents

Publication Publication Date Title
US20110159000A1 (en) Antibodies with mannose binding lectin effector function for inhibiting pathologic inflammatory conditions
EP0805871B1 (de) Antikörper gegen cd30, die proteolytische spaltung und abgabe des membrangebundenen cd30 antigens verhindern
JP4667383B2 (ja) アグリコシル抗ｃｄ１５４（ｃｄ４０リガンド）抗体およびその使用
TWI531581B (zh) 抗－ＣＤ４０抗體之靜默Ｆｃ變體
US20100297008A1 (en) Ganglioside associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumors
JP3565351B2 (ja) 免疫応答を惹起するための、多数エピトープ含有抗原の再構成法および組成物
KR20160129698A (ko) 항-b7-h5 항체 및 이의 용도
US20030215450A1 (en) Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
JP2018528258A (ja) 改良された結合、機能的および安全性特性を有する抗ｃｄ１５４抗体ならびにヒト免疫療法での使用
EP2380585B1 (de) Verfahren zur Behandlung von Autoimmunerkrankungen
US20110038860A1 (en) Methods for inhibition of polyclonal b cell activation and immunoglobulin class switching to pathogenic autoantibodies by blocking cd1-mediated interactions
CN103588882A (zh) 针对人cd22抗体的抗独特型抗体及其应用
WO2001082960A1 (en) Inhibition of polyclonal b cell activation and immunoglobulin class switching to pathogenic autoantibodies by blocking cd1-mediated interactions
KR100372958B1 (ko) 면역반응을개시시키기위해다중에피토프항원의입체형태를변화시키기위한방법및조성물
AU2010244859B2 (en) Antibodies that recognize sulphatides and sulphated proteoglycans and the use thereof
JP4247783B2 (ja) 免疫応答を惹起するための、多数エピトープ含有抗原の再構成法および組成物
CN112867785A (zh) 通过抗体介导的特定肠道细菌的中和作用治疗免疫性疾病
AU2011224032A1 (en) Aglycosyl Anti-CD154 (CD40 Ligand) Antibodies and Uses Thereof
Sordé Anti-inflammatory effects of intravenous immunoglobulin (IVIg): what are the mechanisms of action?
Geldart Efficacy and toxicity of anti-CD40 monoclonal antibodies in the treatment of malignancy
JP2001055341A (ja) 免疫応答を惹起するための、多数エピトープ含有抗原の再構成法および組成物
JP2007320969A (ja) 免疫応答を惹起するための、多数エピトープ含有抗原の再構成法および組成物

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20110323

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AX Request for extension of the european patent

Extension state: AL BA RS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20110902